Welcome to the international HTA database

Showing [23369 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	NIHR Health Technology Assessment programme	The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Implantable Left Ventricular Assist Device (LVAD) in addition to guideline directed medical therapy (GDMT) in end stage heart failure
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Endobutton® and Retrobutton® for femoral fixation of the anterior cruciate ligament graft
2016	Health Sciences Institute in Aragon (IACS)	Electronic prosthesis for Dysphemia. Effectiveness and safety of electronic devices in improving the fluency of stuttering
2016	National Institute for Health and Care Excellence (NICE)	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel. NICE technology appraisal guidance 391
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Nivolumab for the treatment of renal-cell carcinoma
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, security and economic evaluation of the screening for cryptorchidism
2016	National Institute for Health and Care Excellence (NICE)	Adalimumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 392
2016	NIHR Health Technology Assessment programme	A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	[Report adaptation: health technology assessment of the different dialysis modalities in Italy]
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Dextrometorphan-quinidine for the treatment of pseudobulbar affect
2016	National Institute for Health and Care Excellence (NICE)	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 393
2016	Canary Health Service	[Fetal DNA analysis in maternal blood for the detection of trisomies 21, 18 and 13]
2016	NIHR Health Technology Assessment programme	The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndrome
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ceritinib (Zykadia) - non-small cell lung cancer: locally advanced or metastatic; anaplastic lymphoma kinase (ALK) positive – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Multiplex PCR panels (FilmArray®) to diagnose infections
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure]
2016	National Institute for Health and Care Excellence (NICE)	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 394
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Fractional exhaled nitric oxygen in asthma patients
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure - Addendum to Commission E15-04]
2016	National Institute for Health and Care Excellence (NICE)	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016	Canary Health Service	[Spanish society's willingness to pay for a quality-adjusted life year]
2016	NIHR Health Technology Assessment programme	Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Decitabine (Dacogen) - acute myeloid leukaemia: newly diagnosed de novo or secondary; adult patients of all ages who are not suitable for standard induction chemotherapy
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Extracorporeal shock wave therapy in musculoskeletal disorders
2016	National Institute for Health and Care Excellence (NICE)	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. NICE technology appraisal guidance 396
2016	Canary Health Service	[Effectiveness and cost-effectiveness of surveillance programs to prevent hip dislocation in cerebral palsy]
2016	NIHR Health Technology Assessment programme	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Botulinum toxin for sialorrhea
2016	National Institute for Health and Care Excellence (NICE)	Lumacaftorivacaftor for treating cystic fibrosis homozygous for the F508del mutation. NICE technology appraisal guidance 398
2016	Canary Health Service	[Effectiveness, safety and cost-effectiveness of the flash interstitial fluid glucose monitoring system (FreeStyle Libre®) for type 1 and 2 diabetes mellitus]
2016	NIHR Health Technology Assessment programme	CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - colorectal cancer: advanced or metastatic; high-level microsatellite instability – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Magnetic resonance neurography to study peripheral neuropathies
2016	National Institute for Health and Care Excellence (NICE)	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. NICE technology appraisal guidance 399
2016	Canary Health Service	[Indications, safety, effectiveness and cost-effectiveness of noninvasive brain stimulation in the treatment of mental disorders]
2016	NIHR Health Technology Assessment programme	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016	NIHR Health Technology Assessment programme	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
2016	NIHR Public Health Research (PHR) programme	Change in alcohol outlet density and alcohol-related harm to population health (CHALICE): a comprehensive record-linked database study in Wales
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	High-dose chemotherapy followed by autologous transplantation of hematopoietic stem cells in patients with recurrent childhood medulloblastoma
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab in combination with ipilimumab for treating advanced melanoma. NICE technology appraisal guidance 400
2016	Canary Health Service	[Extracorporeal membrane oxygenation (ECMO) in patients with advanced heart failure or cardiogenic shock]
2016	NIHR Health Technology Assessment programme	EQUATOR Network
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Quizartinib - acute myeloid leukaemia: relapsed or refractory; FLT3-internal tandem duplication (ITD) positive – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Cannabinoids for refractory epilepsy treatment
2016	National Institute for Health and Care Excellence (NICE)	Bosutinib for previously treated chronic myeloid leukaemia. NICE technology appraisal guidance 401
2016	Canary Health Service	[Patient participation in health technology assessment: methodological manual]
2016	NIHR Health Technology Assessment programme	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Percutaneous closure of patent foramen ovale for stroke prevention
2016	National Institute for Health and Care Excellence (NICE)	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016	Canary Health Service	[Safety, clinical effectiveness and cost-effectiveness of stereo-electroencephalography in epilepsy surgery]
2016	NIHR Health Technology Assessment programme	Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Sapacitabine - acute myeloid leukaemia: patients ≥70 years of age; not candidates for standard intensive therapy – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Activated charcoal for preoperative localization of thyroid cancer recurrence
2016	National Institute for Health and Care Excellence (NICE)	Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016	Canary Health Service	[Prognostic genomic tests for localized prostate cancer]
2016	NIHR Health Technology Assessment programme	Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Zoptarelin doxorubicin - endometrial cancer: locally advanced, recurrent or metastatic – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Cryoablation for the treatment of kidney tumors
2016	National Institute for Health and Care Excellence (NICE)	Degarelix for treating advanced hormone-dependent prostate cancer. NICE technology appraisal guidance 404
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Volanesorsen - familial chylomicronemia syndrome – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Rituximab biosimilars
2016	National Institute for Health and Care Excellence (NICE)	Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016	NIHR Health Technology Assessment programme	A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Simtuzumab - liver fibrosis secondary to non-alcoholic steatohepatitis or primary sclerosing cholangitis
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Biomedical treatment for autism spectrum disorders
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Teduglutide (Revestive) - short bowel syndrome: in paediatric patients aged 1-17 years who are dependent on parenteral nutrition
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2016	National Institute for Health and Care Excellence (NICE)	Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. NICE technology appraisal guidance 407
2016	NIHR Health Technology Assessment programme	A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial
2016	NIHR Health Services and Delivery Research programme	Management by geographical area or management specialised by disorder? A mixed-methods evaluation of the effects of an organisational intervention on secondary mental health care for common mental disorder
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Begelomab (Begesand) - graft versus host disease: acute; steroid resistant – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Eye tracking speech-generating devices in disorders involving language, speech and motor skills
2016	National Institute for Health and Care Excellence (NICE)	Pegaspargase for treating acute lymphoblastic leukaemia. NICE technology appraisal guidance 408
2016	NIHR Health Technology Assessment programme	An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Caplacizumab-Thrombotic thrombocytopenic purpura: acquired; acute phase – adjunctive therapy
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Riociguat for the treatment of pulmonary hypertension
2016	National Institute for Health and Care Excellence (NICE)	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. NICE technology appraisal guidance 409
2016	NIHR Health Technology Assessment programme	BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Noninvasive testing for coronary artery disease
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Relebactam with imipenem and cilastatin - multi-drug resistant or carbapenem resistant Gram-negative infections
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Radio-223 (Xofigo®) for the treatment of patients with metastatic cancer
2016	National Institute for Health and Care Excellence (NICE)	Talimogene laherparepvec for treating unresectable metastatic melanoma. NICE technology appraisal guidance 410
2016	Agency for Healthcare Research and Quality (AHRQ)	Improving cultural competence to reduce health disparities
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Autologous haematopoietic stem cell transplantation - multiple sclerosis: relapsing remitting – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Single-use negative pressure wound therapy for chronic and acute wounds
2016	National Institute for Health and Care Excellence (NICE)	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016	Agency for Healthcare Research and Quality (AHRQ)	Early diagnosis, prevention, and treatment of Clostridium difficile: update
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Low dose desmopressin acetate (Noqdirna) - nocturia: idiopathic nocturnal polyuria; symptomatic; in adults – as sole agent or as a combination treatment
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Stem cell therapy in heart failure prevention and progress
2016	National Institute for Health and Care Excellence (NICE)	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2016	NIHR Health Technology Assessment programme	An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Data linkage strategies to advance youth suicide prevention
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dupilumab - atopic dermatitis: moderate to severe; inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Nivolumab for the treatment of non-small cell lung cancer